Chief Financial Officer · Enliven Therapeutics, Inc. (ELVN)

Ben Hohl

FY2025 is the first fiscal year CompBrief holds for Ben Hohl as a named executive officer of Enliven Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$3,443,173

Salary $480,000Stock awards $0

4th of 4 named executive officers at Enliven Therapeutics by FY2025 total.

4 named officers on file for Enliven Therapeutics, FY2025

Ben Hohl’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Enliven Therapeutics’s whole pay program stands against its peers

  • Enliven Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELVN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A).

Free

Get Ben Hohl’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ben Hohl compensation by year

Enliven Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Enliven Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$480,000
Bonus$0
Stock awards$0
Option awards$2,775,279
Non-equity incentive$172,800
Pension and deferred compensation$0
All other$15,094
Total$3,443,173

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Enliven Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182045, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Enliven Therapeutics, Inc. filed document, accession 0001193125-26-182045. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option171,000—$22.47
Option60,084—$22.75
Option100,209—$14.85

Per the Outstanding Equity Awards at Fiscal Year-End table in Enliven Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Enliven Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Richard FairPresident and Chief Executive Officer$11,918,926
Sam KintzFormer President and Chief Executive Officer$8,908,647
Helen CollinsChief Medical Officer$3,501,699
Ben Hohl · this pageChief Financial Officer$3,443,173

The full Enliven Therapeutics compensation record

free company brief

This page is one person within Enliven Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Enliven Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ben Hohl's compensation dossier · One-time report. No refunds.